-

05:33:16 PM

GRNA Stock News

GRNA - GreenLight Biosciences Inc

03/09/23 6:59 AM

Nasdaq : GRNA

GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Human Health R&D Day

Progressing human health pipeline conferring mRNA platform advantages for infectious disease and personalized oncology medicines; pursuing capital efficient strategy targeting unmet medical needs, in both the developed and lower- and middle-income countries (LMICs), pairing focused R&D spend

RHEA-AI

very positive

03/07/23 6:59 AM

Nasdaq : GRNA

GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Plant Health R&D Day

GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, will today outline its pipeline strategy and R&D

RHEA-AI

positive

03/01/23 6:24 AM

Nasdaq : GRNA

conferences

GreenLight Biosciences to Host R&D Day Series on Plant and Human Health Development Strategy

GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today announced it will host a two-part R&D Day Series

RHEA-AI

neutral

02/01/23 7:20 AM

Nasdaq : GRNA

clinical trialcovid-19

GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate

The Rwanda FDA has given regulatory approval to GreenLight to start a Phase I/II clinical trial of its Covid-19 vaccine candidate in Rwanda. This phase I/II clinical trial is the first step in GreenLight’s integrated strategy of bringing a universal Covid-19 mRNA vaccine to market globally. By

RHEA-AI

neutral

01/09/23 7:20 AM

Nasdaq : GRNA

GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines

The effort will combine GreenLight’s mRNA design and manufacturing expertise with EpiVax’s advanced Ancer® pipeline for personalized cancer vaccine design Epivax Therapeutics, Inc. will contribute a proprietary set of immunoinformatics tools for rapidly identifying and differentiating highly

RHEA-AI

very positive

11/09/22 5:07 PM

Nasdaq : GRNA

earnings

GreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

Working toward clinical trial initiation for COVID vaccine candidate in 2023 Shingles vaccine candidate selection planned for 2023 in partnership with Serum Institute of India Calantha™, Colorado potato beetle solution, commercial launch planned for 2023, subject to regulatory approval Honeybee

RHEA-AI

positive

11/07/22 11:25 AM

Nasdaq : GRNA

conferences

GreenLight Biosciences to Participate in Upcoming Investor Conferences in November

GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the potential of RNA to address some of the world’s toughest problems in human health and agriculture, today announced that Dr. Andrey Zarur, CEO, and Susan Keefe,

RHEA-AI

neutral

10/12/22 6:54 AM

Nasdaq : GRNA

GreenLight Biosciences announces realignment to focus on near-term value drivers

GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for everyone and dedicated to developing health solutions for every person on our planet, today announced

RHEA-AI

very positive

10/05/22 9:35 AM

Nasdaq : GRNA

partnership

GreenLight Biosciences and Queensland University of Technology partner to tackle destructive fall armyworm using RNA

GreenLight Biosciences and Queensland University of Technology (QUT) partner to create a solution for fall armyworm Fall armyworm is one of the most destructive insect pests on the planet, causing more than US$2 billion in annual crop loss worldwide The Australian government has been searching for

RHEA-AI

very positive

08/15/22 7:30 AM

Nasdaq : GRNA

earnings

GreenLight Biosciences Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

GreenLight raised $108.4 million in private placement led by S2G Ventures with strong participation from existing and new investors with cash expected to fund critical programs through the first half of 2023. GreenLight and Samsung Biologics completed their first commercial-scale engineering run

RHEA-AI

positive